- Home
- LSF vs BEAT Comparison
LSF vs BEAT Comparison
Compare LSF & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- BEAT
- Stock Information
- Founded
- LSF 2015
- BEAT 2015
- Country
- LSF United States
- BEAT United States
- Employees
- LSF N/A
- BEAT N/A
- Industry
- LSF Packaged Foods
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- LSF Consumer Staples
- BEAT Technology
- Exchange
- LSF Nasdaq
- BEAT Nasdaq
- Market Cap
- LSF 62.0M
- BEAT 63.5M
- IPO Year
- LSF 2020
- BEAT 2021
- Fundamental
- Price
- LSF $2.74
- BEAT $1.56
- Analyst Decision
- LSF Strong Buy
- BEAT Buy
- Analyst Count
- LSF 1
- BEAT 1
- Target Price
- LSF $12.00
- BEAT $8.00
- AVG Volume (30 Days)
- LSF 90.1K
- BEAT 86.1K
- Earning Date
- LSF 11-10-2025
- BEAT 11-13-2025
- Dividend Yield
- LSF N/A
- BEAT N/A
- EPS Growth
- LSF N/A
- BEAT N/A
- EPS
- LSF N/A
- BEAT N/A
- Revenue
- LSF $48,146,862.00
- BEAT N/A
- Revenue This Year
- LSF $21.88
- BEAT N/A
- Revenue Next Year
- LSF $20.86
- BEAT $28.23
- P/E Ratio
- LSF N/A
- BEAT N/A
- Revenue Growth
- LSF 17.73
- BEAT N/A
- 52 Week Low
- LSF $2.52
- BEAT $0.91
- 52 Week High
- LSF $10.90
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- LSF 18.84
- BEAT 44.23
- Support Level
- LSF $2.52
- BEAT $1.62
- Resistance Level
- LSF $4.30
- BEAT $1.74
- Average True Range (ATR)
- LSF 0.32
- BEAT 0.13
- MACD
- LSF -0.19
- BEAT -0.01
- Stochastic Oscillator
- LSF 8.07
- BEAT 30.88
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.